Biohaven Pharmaceuticals IPO

5/4/2017

IPO

$168,300,000

We currently estimate that we will use the net proceeds from this offering, together with our existing cash, as follows: approximately $73.1 million to fund continued research and development of rimegepant, including initiating and completing our two planned Phase 3 clinical trials for the acute treatment of migraine, and initiating our planned long-term safety study of rimegepant; approximately $24.2 million to fund continued research and development of BHV-3500 for the prevention of chronic and episodic migraine; approximately $9.6 million to complete our ongoing Phase 2/3 clinical trial of trigriluzole for the treatment of SCA; approximately $10.3 million to fund continued research and development of BHV-5000 for the treatment of breathing irregularities associated with Rett syndrome, including completion of our planned Phase 1 clinical trial for this indication; approximately $5.6 million to repay aggregate indebtedness under our credit agreement with Wells Fargo Bank, National Ass

Publicly-held

Biopharmaceutical

215 Church St.
New Haven, CT 06510
USA

Undisclosed

Not Recorded

Biohaven Pharmaceuticals (NYSE: BHVN) is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.